164 related articles for article (PubMed ID: 27738482)
1. Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes.
Suzuki K; Mitsuma Y; Sato T; Anraku T; Hatta M
J Clin Med Res; 2016 Nov; 8(11):805-814. PubMed ID: 27738482
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Takeishi S; Tsuboi H; Takekoshi S
Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
[TBL] [Abstract][Full Text] [Related]
3. Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study.
Bu S; Zhang X; Zhu H; Shuai Y; Xing X; Yang W;
Diabetes Ther; 2017 Aug; 8(4):887-898. PubMed ID: 28623551
[TBL] [Abstract][Full Text] [Related]
4. Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo
Wiesli P; Schories M
Diabetes Ther; 2018 Dec; 9(6):2325-2334. PubMed ID: 30302721
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
6. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes.
Rosenwasser RF; Rosenwasser JN; Sutton D; Choksi R; Epstein B
Drugs Today (Barc); 2014 Nov; 50(11):739-45. PubMed ID: 25525634
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P
Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
[TBL] [Abstract][Full Text] [Related]
8. Adding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study.
Jin Y; Sun X; Zhao X; Zhu T
Diabetes Ther; 2017 Jun; 8(3):611-621. PubMed ID: 28349442
[TBL] [Abstract][Full Text] [Related]
9. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
[TBL] [Abstract][Full Text] [Related]
10. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
[TBL] [Abstract][Full Text] [Related]
11. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
[TBL] [Abstract][Full Text] [Related]
12. Assessment of three fasting plasma glucose targets for insulin glargine-based therapy in people with type 2 diabetes mellitus in China: study protocol for a randomized controlled trial.
Yang W; Yang Z; Zhao J; Lu H; Luo T
Trials; 2016 Sep; 17(1):470. PubMed ID: 27669747
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring.
Kawaguchi Y; Sawa J; Kumeda Y
Diabetes Ther; 2020 Dec; 11(12):2945-2958. PubMed ID: 33063270
[TBL] [Abstract][Full Text] [Related]
14. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.
Eliaschewitz FG; Calvo C; Valbuena H; Ruiz M; Aschner P; Villena J; Ramirez LA; Jimenez J;
Arch Med Res; 2006 May; 37(4):495-501. PubMed ID: 16715577
[TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
Gupta A
Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus.
Lechleitner M; Roden M; Haehling E; Mueller M
Wien Klin Wochenschr; 2005 Sep; 117(17):593-8. PubMed ID: 16395988
[TBL] [Abstract][Full Text] [Related]
17. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
Davies M; Evans R; Storms F; Gomis R; Khunti K
Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
[TBL] [Abstract][Full Text] [Related]
18. Insulin Glargine Combined with Oral Antidiabetic Drugs for Asians with Type 2 Diabetes Mellitus: A Pooled Analysis to Identify Predictors of Dose and Treatment Response.
Gu T; Hong T; Zhang P; Tang S; Bi Y; Lu H; Men L; Ma D; Zhu D
Diabetes Ther; 2018 Apr; 9(2):771-787. PubMed ID: 29524190
[TBL] [Abstract][Full Text] [Related]
19. Addition of Basal Insulin to Oral Antidiabetic Agents in Patients with Inadequately Controlled Type 2 Diabetes Leads to Improved HbA1c Levels: Metabolic Control, Frequency of Hypoglycemia, and Insulin Titration Analysis as Results of a Prospective Observational Study (BALI Study).
Brož J; Janíčková Ždárská D; Štěpánová R; Kvapil M
Diabetes Ther; 2019 Apr; 10(2):663-672. PubMed ID: 30788806
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial.
Yin TT; Bi Y; Li P; Shen SM; Xiong XL; Gao LJ; Jiang C; Wang Y; Feng WH; Zhu DL
Diabetes Ther; 2018 Jun; 9(3):1253-1267. PubMed ID: 29744819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
